ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DNTH vs ERAS // ENTERPRISE SCALE & MARKET CAP

Dianthus Therapeutics Inc. (NASDAQ) VS. Erasca Inc. (NASDAQ) • 15-METRIC TALLY: DNTH 3 — ERAS 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ERAS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNTH VS. ERAS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DNTH ERAS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -30.70% -35.00% +4.30 DNTH /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.79% -1.82% -0.97 ERAS /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 DNTH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.8 45.3 +1.50 DNTH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.08 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 20.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $4.61B $5.02B -$411.2M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DNTH REV ERAS REV DNTH GROSS % ERAS GROSS % DNTH FCF ERAS FCF
FY 2025 $2.0M $394.5M — — -$129.2M -$95.6M
FY 2024 $6.2M $502.8M — — -$78.5M -$109.5M
FY 2023 $2.8M $396.3M — — -$37.0M -$101.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNTH // BETA 1.08
ERAS // BETA —